Showing posts with label robots. Show all posts
Showing posts with label robots. Show all posts

Tuesday, May 5, 2015

I Buy Adept Technology, again

I just bought a small amount of Adept Technology (ADEP) at $5.92 a share. I'll be watching to see if future developments warrant further investment.

Adept Technology is a small cap company that makes industrial robots. It has been around for quite a while. I like robots. This is my second go round with Adept. Despite my trying to be a long-term investor, and my shifting to biotechnology stocks, I bailed out of ADEP once already, and with good reason. If you do decide you like ADEP, be wary.

I originally bought Adept in 2012, when it was in deep trouble due to falling sales. I bought at $3.95 on 11/5/2012 and then at $2.94 on 11/09/2012. My final purchase was for $3.34 on 2/8/2013.

It was a turn around bet, and after Adept hit bottom some small brokerages started recommending it. The stock rose faster than its revenue, and so I started selling. I sold at $7.92 on 10/7/2013, then at $14.45 on 12/26/2013, and the remainder at $18.63 on 2/10/ 2014. The stock went even higher than that, but neither sales nor profits justified the high prices, to me.

Of course eventually the stock price stalled and started falling. I continued to cover Adept at OpenIcon. You can read my notes about the Adept Technology March 2015 quarter results and analyst conference.

My reasoning for today's purchase is that the current market cap is about $80 million. In March revenue was $14.1 million, and June quarter guidance is for revenue between $13.5 and $15.0 million. Margins are not great, so they are losing money, but could hit profitability on a bit more revenue.

But feedback on their mobile robots (for warehouses, etc.) is good, and they expect to sell significantly more as the year progresses, though perhaps in a lumpy manner.

My rule of thumb for P/E is 20. So they need $4 million per year, or $1 million per quarter, to justify the current price. I think Adept could reach $1 million profit per quarter by the end of the year. They could also fail for a variety of reasons, including less than expected sales of their old-line, assembly-line robots, or of the new mobile robots.

Again, I hope that Adept succeeds gradually, and the stock price just goes up to reflect the level of success. So I can be a happy, long term investor, rather than having to sell after concluding that the stock price has been pumped up beyond reason.

Especially when investing in micro-cap stocks it really pays to

Keep Diversified!

Tuesday, September 10, 2013

Intuitive Surgical, Mylan, and Regeneron

I have had three Seeking Alpha articles published since my last post:

Regeneron Pipeline Worth Tens of Billions in Market Capitalization

Mylan Pursues Global Generics Dominance Strategy

Intuitive Surgical Market Saturation Could Be Brief

All three of these biotechnology companies are part of the Nasdaq 100, which I have been plowing through, looking toward my next round of investment. Each has something unique to offer. As detailed in the articles, each of them, at the current price and based on current information, looks like a good long-term investment. But I'll be doing considerably more research before making any actual purchases.

Wednesday, August 28, 2013

Alexion Pharmaceuticals and Adept Technology

I have added Alexion Pharmaceuticals (ALXN), a creator of therapies for blood disorders, to my list of covered stocks. I do not currently own ALXN. You can read my Seeking Alpha article: Alexion Pharmaceuticals Offers Long-Term Value or look at my notes from the latest analyst call, Alexion Pharmaceuticals Q2 2013 Analyst Conference Summary.

Connected only by alliteration, we have robot manufacturer Adept Technology (ADEP), which had quite a stock boost today based on June quarter (fiscal Q4) results. My notes are at Adept Technology Q4 2013 Analyst Call Summary. You can see my prior prediction that this should be a turn-around quarter at Adept Technology Order May Signal Turnaround published at Seeking Alpha on June 28, 2013.

I do own ADEP stock.

Monday, November 5, 2012

I Buy Adept Technology (ADEP)

Just a brief note that I bought a small initial position in Adept Technologies, symbol ADEP. You can read my prior assessment at Adept Technology First Look.

This is a very long term investment for me. I have no reason to think Adept is going to go up in price in the near future. There will be an Adept Technology conference call on November 8, this Thursday. I will take notes on it and post them. See my Adept Technology Analyst Conferences page for a link.

I decided to go ahead with the ADEP purchase because I believe there is a future in robotics and that Adept is addressing a significant unmet need. Adept has grown both by acquisitions and by organic growth and appears to be well-managed. Needless to say, that does not guarantee success.

So keep diversified!

Thursday, August 30, 2012

Adept Technology (ADEP) Initial Look

Adept Technology is a Pleasanton, California based maker of robotic machines for materials handling. I was mentioned in a New York Times article recently, which I read because of my interest in robots and artificial intelligence. I decided to take a look at the company as a potential investment. Yesterday Adept (ADEP) released its June quarter (fiscal Q4) results, and I listened to the analyst conference. You can read my notes at: Adept Technology fiscal Q4 2012 notes.

The first thing that individual investors should note is the Adept has a small market capitalization and is not yet profitable. Revenue in the quarter was substantial, however, at $17 million. Net income was negative $360,000, which is within sight of break-even. However bright the future of robotics and Adept might be, it needs to be treated as a risky stock. The stock price ran up after the Times article, and is falling today along with most of the market. Right now it is at $4.30, which would give it a market capitalization of $45.3 million.

I certainly don't consider a young technology company with an annual revenue run rate approaching $70 million to be overpriced when the market cap is $45.3 million and it is running near break-even.

Judging mainly from the conference, Adept makes three basic types of robots, all of which are based on artificial intelligence applied to video, as well as the usual need to manipulate the robots themselves. It mainstay is robots used in the manufacture of hard disk drives.

It has also introduced robots for handling semiconductor wafers, and has a first client for these mobile robots in Singapore.

A third line is designed to rapidly pack agricultural products in plastic clamshell packaging, and there is a California company that is the first customer and proving ground for this product.

It is tempting to plunge in and buy an initial stake of ADEP, but I am going to follow my usual path of being patient and doing more research. There are many robotics companies already, and while there are a lot of applications that could benefit from robots, it is important to understand the competition. Also, I need to read the more recent SEC filings, which I have not done yet.

I already own stock in a medical robotics company, Hansen Medical, and in a manufacturer of microcontrollers used in robotics, Microchip.

I should mention that Adept raised $3 million in the quarter through a new stock issue, and has less than $9 million in cash on hand. In addition to stock dilution through stock-based compensation, there could be a need to raise more cash.

Going forward, I would hope to see better margins on the newer robot lines. If they are valuable to customers, they should be valuable enough to price at a point where there are profit margins for Adept. Otherwise they are just having fun with robots and are not an investment-grade company.

My initial impression of Adept Technologies is very positive overall. At the same time there are a lot of alternatives for my (or your) investment cash. If I do start buying Adept I probably will report that only after the fact. Often I follow stocks for years without ever buying in.

Disclaimer: I have no relationship to ADEP and currently do not own stock. I may buy ADEP at any point without prior notice

See also: http://www.adept.com/

Monday, May 9, 2011

Hansen Medical Ships Just 2 Sensei Systems in Q1

Hansen Medical, maker of robotic controlled catheters for surgery, showed one-time GAAP net income for its first quarter of 2011, reporting results to the analyst conference call on May 4th.

A $23 million sale of intellectual property to Philips medical division was the cause of the profit. Hansen (HNSN) is still essentially in start up mode, losing money each quarter while further developing its Sensei systems for catheter based surgery.

In the quarter Hansen shipped only two new Sensei systems, but it recognized revenue on five systems. Hansen only recognizes revenues on a system when it has been installed, surgeons have been trained, and the system is in actual use. At the end of the quarter there wree 13 systems that had been shipped but not booked for revenue.

Two systems is a slow pace, but shipments have been slow lately. Since each procedure requires a new catheter, it is notable that 693 catheters were shipped in the quarter, up 4% from Q4 and 9% from year-earlier. Most catheters are used for electrophysiology (EP) measurements, until recently the only use approved by the FDA and EMA. However, sale of Lynx catheters for ablation (purposeful destruction of neurons to correct irregular heartbeats) have begun in Europe. I would expect more Sensei systems to sell this year than in 2010 now that ablation can be performed as well as EP.

Management mentioned that one system had already been shipped to a U.S. destination in Q2, and the U.S. sales force has been restructured.

The Philips payment left Hansen with $45 million in cash at the end of the quarter. With the new vascular surgery robots likely (but not certain) to be approved by the FDA and EMA this year, this is plenty of cash to keep the company running until unit sales ramp up, which should lower costs on a per robot basis and allow for sustained profitability.

See my Hansen Medical Q1 2011 analyst conference call summary for a greater level of detail.

I own Hansen Medical stock.

Keep diversified.

See also: Hansen Medical home page

Monday, April 25, 2011

Hansen Medical strategy

Kevin asked why Hansen Medical (HNSN) entered the EP (electrophysiology) market first, and not the vascular market, since, the vascular opportunity is more than 10 times the size of the EP market. (See Hansen Readies Vascular Robots, April 11, 2011)

It's a good question, but with Hansen ending April 19, when Kevin asked, at $3.19, and today ending at $3.48, (up 9% in less than a week) hopefully Kevin bought without waiting for my answer.

I was not covering Hansen when the decision was made, but in a general way it matches the strategy often used by biotechnology companies that need FDA approval for their new drugs or medical devices. Management has to consider development costs and likelihood of a success (defined as an FDA approval to market). The first approval always involves a close FDA look at safety issues. These are relative to specific disease indications. A cold remedy has to be perfectly safe. A cure for an aggressive, malignant cancer that has serious side effects can sometimes get approval if it offers enough life extension to a subset of patients.

Going for vascular surgery for a first approval would have added the risk of surgery to the risk of having a new machine. The important thing for Hansen was to get the basic concept of a catheter robot approved. Since manual catheter EP is fairly safe as invasive procedures go, there was a good chance the only difference with robotic catheters would be more precise control of the catheter. Which is what happened.

Having a validated the Sensei surgical robot, Hansen gained experience in the field by having relatively large numbers of doctors perform EP procedures with Artisan catheters. In something as new as a robot for surgery, there is always room for improvement.

Each type of surgery needs FDA approval, and the tools at the end of the catheter would vary with the type of surgery. With the EP approval Hansen Medical received approval of the basic idea of a robot controlled catheter. When the FDA and EMA (in Europe) look at newer indications, they won't be worried about the basic Sensei system. They will worry mainly about whether there is benefit to doctors and patients from the new surgical procedure.

In addition, Hansen has proven its visualization technology. That has allowed it to raise a lot of cash by licensing that technology. All in all, in retrospect it looks very sensible. Hansen still has to increase its annual robot sales by a factor of about 10 to become profitable, but the technology is proven. If the FDA and EMA approve vascular surgeries, we could see quite a ramp in 2012. For long term investors like myself (I only started buying the stock in 2009), it is not even a vascular story. It is a platform story, with the ramp not being just robots and catheters sold, but whole new types of surgery approved by the FDA at intervals. I like platform stories.

See also:
Hansen Medical
Hansen Medical analysis at Openicon

Tuesday, August 10, 2010

Hansen Medical Q2 2010 Mixed Bag

Hansen Medical (HNSN), which makes robotic catheters for medical procedures, reported $7.0 million revenue for Q2 2010. That is up 159% sequentially from $2.7 million, and up 133% from $3.0 million in the year-earlier quarter.

Unfortunately, while Hansen's long term prospects are good, we are not likely to see a continuing rapid revenue ramp in Q3 or Q4 of 2010.

Hansen's major source of revenue is new Sensei Robotic Catheter Systems, which are currently approved by the FDA for cardiac arrhythmia EP (electrophysiology) procedures. Hansen recognized revenue for 7 systems in Q2, but shipped only 3 systems to customers. Hansen does not recognize revenue on systems until they are in place, working, and physicians have been trained to use them. At the end of the quarter it had a backlog of 14 systems in the field that had not been recognized for revenue.

In comparison, in Q1 Hansen shipped 7 systems but only recognized revenue on 1 system. So for the first half of 2010 10 systems were shipped and revenue was recognized on 8.

These systems run $650,000 to $700,000 each, and are relatively new to the medical community, which has had tight capital equipment budgets the last few years. So both shipments and recognition of revenues vary widely by quarter. That is likely to continue until robotic catheters are adopted for more types of procedures.

There are two main near-term areas where Hansen could sell more robots. The closest is for Atrial Fibrillation (AF) therapy. A clinical trial is already enrolling patients, but results are not likely until well into 2011.

Most promising is using robotic catheters in vascular (blood vessel) procedures. Philips is partnering with Hansen for this, providing partial funding. But this is a development phase product, with no certain plan for clinical trials at present.

Hansen investors will need to be patient. Electrophysiology alone might ramp to a profitable business over the next two or three years, but serious money is unlikely to be made (this is my opinion) until 2012 and after.

On the good side, the stock is dirt cheap. On the cautionary side, nothing guarantees that Hansen will sell more robots for EP, or get FDA or European approval for AF or vascular procedures.

For details see my notes at Hansen Medical Q2 2010 Analyst Conference Call Summary.

So keep diversified!

Wednesday, February 24, 2010

Hansen Medical's Long March

Hansen Medical (HNSN) reported its Q4 2009 numbers yesterday. Although the revenue numbers showed good improvement both sequentially and year over year ($7.2 million, up 56% sequentially from $4.6 million and up 33% from $5.4 million in the year-earlier quarter), revenue does not even meet half of expenses. (See also my Hansen Medical analyst conference summary for Q4 2009).

What we have in Hansen is an opportunity to be a venture-capitalist-equivalent using a listed and liquidly traded stock. This is not uncommon in biotechnology. Starting a biotechnology company is a lengthy process, and venture capitalists like to IPO these stocks long before they reach profitability. Often, several rounds of stock sales are needed to keep the companies going, and many simply go under, as we say in 2008 and 2009 when funding dried up. The risks are high, but so are the potential returns.

At least Hansen is selling its robotic catheter machines. Six were shipped in Q4. They are predicting a seasonally down first half, but total sales of 30 to 35 in 2010, so lets say 8 per quarter.

There are a bunch of problems in developing robotic surgery businesses. That they can be overcome has been proven by Intuitive Surgical (ISRG). Hansen has to get approval from the FDA for each type of surgery for its machines. Also, each type may require the development of a different catheter. Right now the Sensei Robotic System and its Artesian Control Catheter are approved only for electrophysiology (EP).

Just because the first goal of Hansen was to get approval for EP, does not mean that is where the real money is. While certainly useful for EP, flexible catheter robotics has broader uses. With its flexible EP platform a success, Hansen needs to move into other areas. And since the EP business is money losing (and might remain so), capital is needed for research and development.

Fortunately, Hansen both has some cash raised in a stock offerering in 2009 and a partner in Philips Medical Systems. The next big target is peripheral vascular disease. This would seem to be a perfect match for Hansen's technology, and it is a much bigger market than EP. But the machinery has to be perfected, FDA approval obtained, and then surgeons have to be convinced that they should use these rather expensive machines (over $600,000 each).

You can put a target price where ever you like on a stock like Hansen Medical. It was trading for over $20 per share in 2008, now it is under $2.50 per share. Investors thought that once the robots started to be used in hospitals, there would be a continuous ramp-up, and ISRG like stories were told.

I think at $2.50 per share, as long as it is a small part of a risk-balanced portfolio, Hansen is very, very attractive for long-term investors. I mean people who can wait two years or more to see how things develop. [I own HNSN]

There might even be an upside to the EP business while other markets are developed. The catheters cost over $1500 each, and 539 were sold in Q4. It is not far-fetched that the run rate could be pushed up well above current levels; that is one of management's explicit aims.

Europe apparently has a more flexible system regarding robotic medical devices, so there is a possibility that in 2010 we will start seeing more machines sold there than in the U.S. Of the six machines shipped in Q4, 3 went to Europe.

Nibble before you bite, and keep diversified!

See also the Hansen Medical site

Sunday, January 24, 2010

Intuitive Surgical Q4 Analyst Conference

Intuitive Surgical (ISRG) is back in growth mode. At the analyst conference Thursday management reported Q4 2009 revenues that were up 15% sequentially and 40% from the year-earlier quarter.

In Q1, 2009 the recession had impacted even mighty Intuitive, with revenues flat from year earlier.

So while the company has great products, and is doing great, it might be cautious to attribute the good Q4 numbers in part to equipment purchases that were delayed earlier in 2009.

For details see my Intuitive Surgical Q4 analyst conference summary.

While I believe that ISRG will continue to see good growth in the long run as its robots are used for an increasing variety of surgeries, I don't own the stock. Compared to other growth companies the Price/Earnings ratio is rather high, though not at the kind of ridiculous levels we saw before the panic. Investors have done very well with Intuitive, and those who dumped the stock in late 2008/early 2009 now regret their panic.

I do own shares in a much smaller, even more speculative, surgical robotics company, Hensen Medical.

Wednesday, October 21, 2009

Intuitive Surgical Third Quarter Analyst Conference

Intuitive Surgical (ISRG) held its third quarter analyst conference yesterday, October 20, 2009. While Intuitive is actually doing well, especially when you consider the depressed economy, it is not doing as well as investors had hoped. Any stock with a high Price to Earnings (P/E) ration such as Intuitive has is vulnerable to these sorts of let downs.

Revenues were $280.1 million, up 8% sequentially from $260 million, and up 19% from $236 million in the year-earlier quarter. Net income was $64.5 million, up 3% sequentially from $62.4 million, and up 12% from $57.6 million year-earlier. For more details on third quarter results see my Intuitive Surgical Analyst Conference Summary for October 20, 2009.

Those numbers would make ISRG a growth company; for a recession they are stellar. Yet I don't own any Intuitive Surgical stock, and hesitate to buy it at today's price. It is true that if the economy recovers and doctors continue to adopt robotic surgery techniques at a rapid pace, today's stock price can be easily justified by future expectations. But the late debacle should warn us to be careful about assigning high P/Es to stocks.

If you want to criticize Intuitive, you would point to the number of its da Vinci Surgical systems sold in the quarter. At 86, that is down from the 91 sold in Q3 2008. The new generation of systems are pricier, and a good bit of revenue, more than half now, comes from servicing the installed base and supplying instruments and accessories for surgeries performed. So 86 is not a disaster. But recall that Q3 2008 was a time when wiser heads were already starting to be careful with their capital spending. It was not a boom quarter.

Among doctors there is still a great deal of excitment about Intuitive Surgical, the da Vinci systems, and robotic surgery in general. On the other hand, I expect competition in this field to ramp up in the next few years.

Intuitive Surgical may be a bit overpriced, but it is a good stock to buy on dips. However, always be wary of stock prices that are based on investor enthusiasm rather than profits and reasonable expectations of future profits. Even after today's stock drop Nasdaq (which uses non-GAAP measures) is reporting Intuitive's P/E ratio at 48 trailing, 40 forward. That is flying pretty high in this stock market.

So ...

Keep diversified!

Thursday, July 9, 2009

I Buy Hansen (HNSN)

I bought my first shares of Hansen Medical (symbol: HNSN) today at $2.76 per share. It is a very risky move. It is not clear that Hansen is at a short-term bottom. I don't expect the stock to go up significantly until it reports an increasing number of sales for its robotic surgical catheter systems. That can't happen until after the September quarter ends, and may not be until well into 2010. On the other hand, I am looking at Hensen as a long term investment, and it is going for a small fraction of its 52 week high of $20.20.

Hansen was supposed to be the new Intuitive Surgical (ISRG). Unfortunately its timing was bad. It was starting to sell significant amounts of its products, which only began selling in 2007. Their surgical Sensei Robotic Systems run $600,000 each. When the economic turmoil hit last fall, hospitals started delaying orders. Revenues peaked at $10.9 million in Q3 2008. They seemed to be stabilizing after Q4 came in at $7.3 million and Q1 2009 came in at $7.1 million.

In April Hansen sold more stock, raising an additional $35 million. Which was necessary since they were burning over $5 million in cash per quarter, and the recession made it impossible to know when they might become profitable.

On July 6, 2009, the Hansen announced disastrous preliminary second quarter revenues of $3.1 to $3.3 million.

Hence the low stock price. Hence my buying.

Today the company's market capitalization is $103 million. In my book that still makes it an expensive stock considering that its net loss even in its best quarter so far, Q3 2008, was $12 million GAAP. True, cash burn is not that bad, much of it is depreciation of startup costs. Still if they repeated Q3 for an entire year, they would have just under $44 million in annual revenue.

So why am I buying the stock?

I like robots. The results from surgeries with the Sensei system are getting really good feedback. I think a lot of hospitals want these systems. I think that when credit becomes available again, most of the system sales that have been delayed will come through.

I also think that India and China, as well as the U.S. and Europe, are going to be big markets for these machines. India and China both need to rapidly improve medical care for their middle and upper classes. They are in a position to skip straight to the most modern technologies.

Of course I could be wrong on any of my guesses about the future. There is also danger from competition; Hansen is not the only company making medical robots these days.

The Sensei robots with their Artisan Control Catheters are mainly used for electrophysiology (EP) at present, but other uses are being developed.

So on the whole what I now have in Hansen Medical is a biotechnology startup company that has only recently begun to ramp sales of its products. Better still, I bought my position when people finally stopped pricing Hansen as if it is the next ISRG.

See also my summaries of analyst conferences for Hansen Medical.

Thursday, January 29, 2009

Intuitive Surgical (ISRG) on Pause

The Intuitive Surgical management team reported fourth quarter 2008 results to analysts on Thursday, January 22, 2009. They also talked about the outlook for 2009. Unlike most of the biotechnology companies that sell therapeutic drugs, Intuitive (ISRG) did take a hit in Q4. As the leading maker of surgical robots, earlier this year its stock price was sky high. But hospitals have become more cautious buyers of Intuitive's da Vinci systems, which cost over $1 million each.

For details on Tuesday's events, see my summary of the Q4 2008 Intuitive Surgical analyst conference. Here I'll concentrate on key take aways.

Revenues of $231.5 million were only down 2% from the third quarter, and were up 22% from year-earlier. The problem for Intuitive's stock price is that investors became use to hypergrowth. It peaked at $357.98 per share in 2008. Today you can buy it at around $104.

Buying opportunity? I don't own the stock, but I'm thinking about buying. It has been obvious for several years that this would be a great company, but its IPO price was rich and it never became reasonable until now. It was last at $100 back in 2006.

Revenues are about evenly split between sales of the actual surgical robots and combined services and accessories (used once, then discarded). Services and disposables revenue will continue to grow as more systems are sold and hospitals use units for more surgeries. The types of procedures surgeons are doing with the robots are increasing. There is a whole sub-industry out there of teaching doctors to use the robots and perfecting various operations with them.

Feedback is that surgeons and hospitals are eager to have these robots. So the hold up is the economy. 85 new systems were sold in the quarter, bringing the installed base to 1111. 30 of the sales were outside the U.S.

The biggest short term concern would be that orders were delayed in December. Are those sales going to go through in Q1? When will hospitals feel confident enough to cause Intuitive to go back to unit growth? No one really knows. Guidance is for system sales to be flat in 2009 compared to 2008. They expect total revenues to be up about 15% in 2009, based on increased services and disposables revenue.

If the economy does not pick up, then a lot less systems may be sold. But given that the machines help hospitals make profits, and many surgeons are excited to have them, if I had to guess I'd say if the economy comes off its low, Intuitive will go back into growth mode as hospitals release funds.

Long term, this is a great stock. Short term, I'd say the middle of the road is slow growth. GAAP earnings were $51 million in the quarter, so say $200 million for 2009. At today's market capitalization of $4 billion, that gives a price to earnings ratio of 20. You can get an even better ratio if you use non-GAAP numbers.

Friday, January 9, 2009

Hansen Medical (HNSN) Coverage Begins

I am now covering Hansen Medical (HNSN) at this blog and at OpenIcon. That means that I plan to write a summary of Hansen's quarterly analyst conferences. Hansen announced preliminary results for its fourth quarter (Q4) of 2008 today, but that gives no where near the insight of the full presentation to analysts that should take place later this month.

Hansen makes robotic catheters. That interests me because it combines my interest in robotics (and machine intelligence) with with my interest in biotechnology. Also, I am going to start covering Intuitive Surgical (ISRG) [See also my Intuitive Surgical analyst conferences page], which has a great business model and has made some investors very happy. I don't own stock in either Intuitive or Hansen, but if their prices remain in the bargain basement and I like what I learn from further scrutiny, I am likely to pick them up at some point this year. That won't effect the stock price either way because I currently play with very small sums of money.

Hansen's rapid growth did not continue in Q4, but they did not do badly either. They shipped 11 Sensei systems and revenues will be above $7 million. Given the financial turmoil in Q4, I think anything above zero shipments should give investors confidence in the long-term prospects of the company. Hansen's main difficulty is that it is losing money while trying to grow. At some point if margins do not improve on increased sales, money is going to have to come from outside. If it comes through a stock sale, that will hurt current investors. Borrowing money, if it is even possible, involves its own risks.

I'll know a lot more and hope to share my first Hansen Medical analyst conference summary with you soon.

Keep diversified!